Pathogenesis and Therapies of SARS-CoV-2

Dear Colleagues,

Four years has passed since the SARS-COV-2 virus was identified as the causative agent of the COVID-19 pandemic, which has so far affected millions of people worldwide, with nearly 7 million confirmed deaths. COVID-19 thus poses a challenge to medical science.

The Guest Editors of this Special Issue hope to construct the framework of a Special Issue dedicated to the pathogenesis and therapy of COVID-19. An important reason for bringing together the findings on this disease is the concern that SARS-COV-2 will remain a significant medical problem in the near future; the number of cases is increasing again (as of December 2023). On the other hand, it is no coincidence that this year's Nobel Prize in Medicine (Karikó and Weissman) is closely linked to the development of an anti-COVID vaccine for the first time based on modified mRNA molecules. It is likely that, as with AIDS some 40 years ago, the mobilisation of medical science will not only bring new therapies for the disease, but also significantly accelerate progress in virology, immunology, and respective clinical disciplines.

Therefore, this Special Issue aims to bring together research on COVID-19, including SARS-COV-2 genomics and mutations, pathomechanisms of acute COVID-19 infection, with special attention paid to respiratory disease (including COVID-associated ARDS), immune system activity, and nervous system manifestations. It will also focus on the under-researched long-COVID syndrome (post-COVID-19 conditions). Finally, we invite you to publish studies on the discovery and development of new antiviral agents capable of inhibiting SARS-COV-2 replication in humans, as well as on the mechanisms and future prospects of anti-coronavirus vaccines.

Dr. Grzegorz Przybylski
Dr. Piotr Kopiński
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ARDS in COVID-19
• COVID-19 therapies
• COVID-19 vaccines
• immune systems in COVID-19
• long-COVID pathogenesis
• SARS-Cov-2 genomics
• SARS-Cov-2 variants
• T-cells in COVID-19